We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies.
Together we can overcome.
We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies.
Together we can overcome.
Mindmed Announces Voting Results for Annual General and Special Meeting
Solving for mental illness and addiction requires a novel approach
Transcending traditional mental healthcare to treat Anxiety
Unlocking a new kind of healing for ADHD & Addiction
Developing new compounds, therapies, methods and technologies to optimize patient outcomes
Patients and therapists deserve care that transcends traditional symptom management cycles, advancing long-term mental healing.
View our approachRigorous science of novel psychedelic compounds, therapies, and healing technologies in collaboration with leading institutions and researchers to make faster discoveries, together
Conducting clinical trials of psychedelic inspired medicines and experiential therapies within existing regulatory pathways to ensure the most effective & transformative healing experience possible
We hold ourselves and our products to the highest levels of safety, efficacy, and accessibility so psychedelic inspired medicines and experiential therapies can one day reach patients in need
Groundbreaking R&D In the Birthplace of LSD: Basel, Switzerland
Training a New Generation of Psychiatrists at NYU
Studying the Science of Microdosing with Experts at Maastricht University
Mindmed Announces Voting Results for Annual General and Special Meeting...
MindMed to Participate in the Jefferies Global Healthcare Conference...
MindMed Appoints Schond L. Greenway as Chief Financial Officer...
Opioid Use Disorder: Zolunicant's Potential for Unmet Treatment Needs...
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development...
MindMed named one of 36 startups that could change the world
MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”
Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.
Robert Barrow
Chief Executive Officer and Board Director
Miri Halperin Wernli, PhD
Executive President and Board Director
Cynthia Hu, JD
Chief Legal Officer & Corporate Secretary
Daniel R Karlin, MD MA
Chief Medical Officer
Schond L Greenway, MBA
Chief Financial Officer
Francois P Lilienthal, MD MBA
Chief Commercial Officer
Robert Silva, PhD
VP, Head of Development
Robert Malenka, MD PhD
Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University
Peter Bergethon, MD
Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.
Robert Dworkin, PhD
Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester
Maurizio Fava, MD
Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)
Maria A Oquendo, MD PhD
Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania
Kenneth Alper, MD
Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine
Peter Gasser, MD
Clinical Advisor
Stanley D Glick, MD PhD
Scientific Advisor
Matthew W Johnson, PhD
Clinical Advisor
Kim PC Kuypers, PhD
Scientific Collaborator & Advisor
Matthias Liechti, MD PhD
Scientific Collaborator & Advisor
Carol Vallone
Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee
Natalie Wheeler, PhD
Medical Science Liaison with Dova Pharmaceuticals
John Rotrosen, MD
Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry
Andreas Krebs
Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee
Brigid Makes
Board Director, Chair of Audit/Finance Committee, Member of Compensation Committee, Member of Nomination and Governance Committee
Carrie Liao, CPA
VP, Corporate Controller & Principal Accounting Officer
Peter Mack, PhD
VP, Pharmaceutical Development
Carole Abel, MBA
VP, Programs and Portfolio Office (PPO)
You are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
